Hypermethylated in cancer 1 (HIC1) is an epigenetically regulated transcriptional repressor that functionally cooperates with p53 to suppress age-dependent development of cancer in mice. Here we show that the mechanism by which the loss of HIC1 function promotes tumorigenesis is via activating the stress-controlling protein SIRT1 and thereby attenuating p53 function. HIC1 forms a transcriptional repression complex with SIRT1 deacetylase, and this complex directly binds the SIRT1 promoter and represses its transcription. Inactivation of HIC1 results in upregulated SIRT1 expression in normal or cancer cells; this deacetylates and inactivates p53, allowing cells to bypass apoptosis and survive DNA damage. Inhibition of SIRT1 function in cells without HIC1 abolishes the resistance to apoptosis. Since aging increases promoter hypermethylation and epigenetic silencing of HIC1, we speculate that the resultant upregulation of SIRT1 may be a double-edged sword that both promotes survival of aging cells and increases cancer risk in mammals.
Introduction
Epigenetic gene silencing can disrupt tumor suppressor gene function as an alternative to inactivating genetic mutations (Jones and Baylin, 2002) . Tumor suppressor HIC1, an essential gene for mammalian development (Carter et al., 2000) , is epigenetically inactivated but not mutated in human cancers (Wales et al., 1995) . Germline disruption of one copy of the gene predisposes mice to an age-and gender-dependent spectrum of malignant tumors in which the wild-type Hic1 allele promoter is hypermethylated (Chen et al., 2003) . HIC1 synergizes in tumor suppression with p53. Germline disruption of one copy each of Hic1 and p53 on opposite chromosomes (trans) or on the same chromosome (cis) in mice results in an altered spectrum, earlier appearance, increased prevalence, and aggressiveness of tumors as a tumor suppressor and how it cooperates with p53 remain unclear.
HIC1 encodes a zinc-finger transcriptional factor (Wales et al., 1995) that represses transcription through two autonomous repression domains (Deltour et al., 1999 (Deltour et al., , 2002 . The N-terminal POZ domain is conserved from yeast to human and mediates protein-protein interaction (Bardwell and Treisman, 1994) (Guarente, 2000) . Sir2p is required for yeast life span extension upon calorie restriction (Lin et al., 2000) , and the reduction of one copy of the Sir2 gene shortens yeast replicative life span, whereas the addition of an extra copy of the Sir2 gene extends life span (Kaeberlein et al., 1999) . Similarly, an additional copy of the Sir2 homolog in C. elegans extends its life span (Tissenbaum and Guarente, 2001 ). Small molecules that enhance Sir2 enzymatic activity also prolong life span of yeast and worm (Howitz et Given that HIC1 and p53 functionally cooperate in tumor suppression and that overexpression of p53 transactivates HIC1 in cancer cells (Guerardel et al., 2001 ; Wales et al., 1995), we have previously proposed that HIC1 may be involved in a feedback regulation of p53 in the process of tumorigenesis ). We now demonstrate that HIC1 regulates p53-dependent apoptotic DNA-damage responses. HIC1, via the POZ domain, is complexed with SIRT1, and both HIC1 and SIRT1 bind directly to the promoter of SIRT1 itself and thus control homeostatic SIRT1 expression. This interaction and the transcriptional regulation of SIRT1 appear essential for DNA-damage responses controlled by p53, whose activity is modulated through deacetylation by SIRT1. Therefore, this study provides evidence that the longevity-regulating protein SIRT1 is under the direct control of tumor suppressor HIC1 and that the roles of SIRT1 in regulating cellular responses to DNA damage involve a complex feedback loop encompassing HIC1 and p53. Since heterozygous loss of Hic1 predisposes mice to late-onset tumor development, and aging itself increases promoter hypermethylation and epigenetic silencing of Hic1, we discuss the possibility that resultant upregulation of SIRT1 could both prolong survival of aging cells and also increase the risk of cancer.
Results

HIC1 Regulates p53-Dependent Apoptotic DNA-Damage Response
To study mechanisms underlying HIC1 tumor suppression, we first examined the impact of Hic1 disruption on mouse embryonic fibroblasts (MEF). MEF from Hic1 −/− mice grew normally and had no significant difference in their karyotypes compared to wild-type MEF (data not shown). However, these cells had a markedly abnormal response to DNA damage. When treated overnight with increasing etoposide concentrations, which induce double-strand DNA breaks, wild-type MEF began to die one to two days after removal of the drug. However, (Figure 2A ). We also isolated individual p53 knockdown clones by limiting dilution and found that six clones with more than 75% knockdown of p53 were more resistant to DNA damage than mock knockdown ( Figure 2B ), suggesting reliance of HIC1 on p53 for mediating an apoptotic response. Notably, significant cell death still occurred in all six p53 knockdown clones with Ad/HIC1 infection ( Figure 2B ), either due to residual amounts of p53 or additional pathways being involved. Consistent with the role of p53 in HIC1-mediated apoptosis, overexpression of HIC1 in breast cancer cell line MDA-MB-231, which has a null p53 status, did not confer additional impact on DNA damage-induced apoptosis (Figure 2C ).
HIC1 Interacts with SIRT1 through POZ Domain
We next searched for potential mechanisms through which HIC1 might mediate p53-dependent DNA-damage control. As mentioned above, the HIC1 N-terminal POZ domain represses transcription in a manner that is resistant to treatment of cells with TSA ( Figure 3A) . The TSA-resistant histone deacetylase SIRT1 regulates p53 for stress and DNA-damage response, and we therefore hypothesized that the HIC1 POZ domain might recruit SIRT1 for transcriptional repression. By overexpressing both HIC1 and mouse SIRT1 in COS7 cells, we observed such interaction in that immunoprecipitation of HIC1 with an affinity-purified HIC1 antibody that is specific to a C-terminal peptide of the protein conserved We then determined whether the Hic1 POZ domain is sufficient to mediate the above interaction. By coexpression in COS-7 cells, HA-tagged fusion protein for the Hic1 POZ domain coimmunoprecipitated with mouse SIRT1 in an HA-POZ dose-dependent manner ( Figure  3D ), suggesting that the Hic1 POZ domain can, indeed, directly or indirectly interact with SIRT1 in a complex. This interaction has biological significance since a mutant HIC1 construct with POZ-domain truncation, expressed from an adenoviral vector (Ad/⌬POZ), failed to mediate the apoptotic DNA-damage response as does wild-type HIC1 ( Figure 3E ). Together, these data suggest that HIC1 recruits SIRT1 through its N-terminal POZ domain and that this interaction is crucial for the biological function of HIC1 in mediating DNA-damage responses. We found that overexpression of HIC1 suppressed levels of SIRT1 in MCF-7 cells 2-fold, and the mutant HIC1 with POZ domain deletion failed to induce such repression ( Figure 4C ). To further characterize this repression, we isolated a 2.1 kb SIRT1 promoter fragment spanning −1231 to +900 bp, which contains the entire SIRT1 promoter CpG island and four potential HIC1 binding sites as described in detail below, to drive a luciferase expression cassette. Again, overexpression of wild-type HIC1 resulted in 3-fold reduction of luciferase activity compared to control lacZ, while HIC1 POZ domain deletion nullified the repression ( Figure 4D ).
HIC1 Directly Regulates SIRT1 Transcription
We next examined whether HIC1 directly represses SIRT1 transcription. Using CAST (cyclic amplification and selection of targets; Wright et al., 1991), we first identified a consensus DNA binding sequence for HIC1 with a core of 5# TGCC(A/C) 3#, which is in agreement with findings by Pinte et al. (Pinte et al., 2004) , and verified specificity of the binding with gel shift assays with mutation controls (data not shown). HIC1 binds poorly to one single consensus site but efficiently to concatemerized sites (Pinte et al., 2004) . We identified two clusters of potential HIC1 binding sites on the human SIRT1 promoter CpG island: one cluster with two adjacent binding sites in the same orientation located at the 5# end of the promoter CpG island, the other cluster with two adjacent binding sites in opposite orientation located at the 3# end of the island ( Figure 4E ). By chromatin immunoprecipitation (ChIP) assay, we found that, endogenously expressed HIC1 protein in human WI 38 cells (Chen et al., 2003 ) specifically bound to the 5# cluster on the human SIRT1 promoter, but not on the 3# cluster or on control GAPDH. These data indicate that two potential binding sites in the same orientation are more favorable for HIC1 binding in vivo than two sites in the opposite orientation. Because we had shown, as seen above, that HIC1 interacts with SIRT1 through its POZ domain, we speculated that the two proteins might form a functional complex in which SIRT1 might participate to help control its own transcription. Indeed, when the ChIP assay was performed with a SIRT1 monoclonal antibody, we found that SIRT1 was associated with the 5# but not the 3# HIC1 binding cluster ( Figure 4E ). To further confirm that HIC1 and SIRT1 might form a stable complex on the SIRT1 promoter, we performed ChIP upon ChIP, consisting of a first round of chromatin immunoprecipitation with HIC1 antibody, elution of the pulldown complex, and a second round of immunoprecipitation with SIRT1 antibody. The bound DNA was then amplified as for individual ChIP for 5# binding sites, as described above. Similarly, we also performed the ChIP upon ChIP with SIRT1 antibody first, followed by HIC1 antibody. In both ChIP upon ChIP assays, HIC1 and SIRT1 specifically bound on the 5# SIRT1 promoter site ( Figure 4F ). Altogether, these data suggest that SIRT1 and HIC1 form a stable transcriptional repression complex that binds the SIRT1 promoter and directly represses SIRT1 transcription.
SIRT1 Is an In Vivo Mediator of Apoptotic Resistance upon Loss of Hic1
Identification of SIRT1 as a direct transcriptional target gene of HIC1 provides an important hint for the proneness of cancer development in aging Hic1 +/− mice and Hic1 +/− p53 +/− mice. Intriguingly, SIRT1 expression is high during early mouse development, before E7.5, and 
SIRT1). For control, normal rabbit IgG was used for the first round of immuoprecipitation and normal mouse IgG for the second (CTL [R, M]). ChIP upon ChIP was also performed with a reverse order of immunoprecipitation, namely, SIRT1 ChIP followed by HIC1 ChIP (SIRT1, HIC1) or control mouse IgG followed by rabbit IgG (CTL [M,R]). PCR amplification of 5# HIC1 binding sites was carried out as in (E). it decreases by 2-to 4-fold after E8.5 and E9.5 (Sakamoto et al., 2004). This trend coincides with the initiation of Hic1 expression after E8 to E9 (Grimm et al., 1999). In adult mice,
HIC1-Mediated Apoptotic Pathway
With all of the above links shown between HIC1, SIRT1, and p53, we last studied whether modulation of apoptosis through these interactions may involve changes in the acetylation status of p53, a key target of SIRT1 deacetylase activity. In MCF-7 cells, total p53 protein levels increased about 2-fold upon etoposide treatment without infection of an adenoviral vector ( Figure 6B) . However, the acetylation of p53 carboxy-terminal lysine residue 382, which is specifically deacetylated by SIRT1 ( Figure 6D) ; instead, it coincided with acetylation of p53 upon Ad/HIC1 infection and drug treatment. Our findings suggest that acetylation of p53 not only enhances its transcriptional activation but also increases its transcriptional repression on apoptotic target genes. Taken together, our data indicate that suppression of SIRT1 in human MCF-7 cancer cells by HIC1 overexpression leads to acetylation of p53, simultaneous activation of proapoptotic factor NOXA, and repression of antiapoptotic factor BCL-2 to elicit apoptosis in response to DNA damage.
Finally, given that Ad/HIC1 infection produced nonphysiologically high levels of HIC1 protein in MCF-7 cells (Figure 1F) , we examined whether, under a more physiological setting, knockdown of HIC1 in human cells could upregulate SIRT1 expression and deacetylate p53. We developed a potent reverse transfection protocol by using lipofectamine-2000 to effectively knock down HIC1 in normal human fibroblast WI 38 cells, in which we were able to eliminate 95% of the HIC1 protein with as little as 12.5 nM HIC1 siRNA (Figure 6F) . We found that SIRT1 protein levels increased by nearly 3-fold upon HIC1 knockdown, compared to no siRNA or a control GAPDH siRNA (Figure 6F ), which effectively knocked down GAPDH (data not shown). Upon DNA damage, levels of total p53 were equally elevated in cells with no siRNA, with GAPDH siRNA, or with HIC1 siRNA, and levels of acetylated p53 in cells with no siRNA and GAPDH siRNA were elevated to a similar level; however, HIC1 siRNA inhibited p53 acetylation 2-fold, and this change correlated well with concomitantly increased SIRT1 expression. Therefore these data, obtained under more physiological conditions in terms of HIC1 expression levels, further support the observations with overexpression of HIC1 and suggest that SIRT1 and p53 are major downstream effectors for HIC1-mediated apoptotic DNA-damage responses. Our current data also suggest the presence of a potential feedback loop as depicted in a model in Figure  7 ; it can engage a complex set of circular interactions to ensure normal homeostatic control by SIRT1 of cellular responses to stress, environmental conditions, and aging, and it can foster oncogenic events when this loop is disabled through a number of potential steps. Given that p53 is able to trans-activate HIC1 ( It has been well demonstrated that the p53 null state is normally achieved at the very late stage of natural cancer progression in humans (Fearon and Vogelstein, 1990) . Similarly, final tumors from Hic1 +/− p53 +/− mice usually have complete loss of the wild-type p53 allele . Nevertheless, during the early steps of tumor progression, an age-related, HIC1-and SIRT1-mediated, posttranslational reduction in p53 function might precede loss of the wild-type p53 allele. This would serve to enhance early progression but would also lead to preservation of some residual p53 activity for mediation of certain essential cellular functions. It must be emphasized, however, that both HIC1 and p53 have other functions that can separately foster tumorigenesis. In our animal models, when the germline dis-ruptions of these two genes are placed on the same chromosome, tumor formation is accelerated and the entire opposite chromosome, harboring two wild-type copies of the genes, is deleted (Chen et al., 2004) ; however, it remains to be determined when this chromosomal loss actually occurs and whether there is a window of time in which Hic1 is hypermethylated before being deleted. When the fully null state for the two genes is simultaneously reached through chromosomal loss in such mice, increased tumorigenesis contribution from Hic1 might occur in a way other than through an age-dependent partial crippling of p53 function. We have already found that dysregulation of another downstream target of HIC1, ephrin A1, appears to contribute to breast cancer tumorigenesis (Watkins et al., personal  communication) . Thus, Hic1 may be a master transcriptional repressor that helps control the regulation of multiple key pathways for which loss of function increases risk for neoplastic events.
Discussion
The HIC1-SIRT1-p53 regulation loop provides an important potential link between our daily lifestyle, diet, aging, and cancer. This is not only because the HIC1 promoter is subjected to age-related hypermethylation but also because the enzymatic activity of SIRT1 is dependent on the cofactor NAD, which directly links metabolism and diet to this regulation loop. Sir2 is required for yeast life span extension upon calorie restriction (CR) (Lin et al., 2000) , and an extra copy of the Sir2 gene can extend the life span of yeast and C. elegans (Kaeberlein et al., 1999; Tissenbaum and Guarente, 2001). CR is the single most effective approach for increasing longevity across species (Weindruch and Walford, 1988). In mice, the SIRT1 level also moderately increases upon CR, and SIRT1 is presumed to likely have similar roles of life span extension in mammals . Given the data from the present study, it appears that longevity and tumorigenesis share certain regulatory functions of SIRT1, and therefore maintaining a delicate equilibrium of these two opposing biological processes would be critical. Controlling cancer risk is an essential step for promoting human longevity. Our present data increase our understanding of how regulation of SIRT1 may be involved in both longevity and tumorigenesis and provide new insight into means through which we may control these processes in a manner that will prove beneficial for human health.
Experimental Procedures
DNA Constructs and Recombinant Viruses
We constructed an adenoviral vector using pAdEasy (He et al., 1998) for HIC1 expression with a 3.2 kb genomic DNA fragment containing the entire HIC1 coding sequence driven by a CMV promoter. For constructing the HIC1 POZ domain mutant, we deleted the amino-terminal 126 amino acids but kept the putative NLS intact. For creating HA-POZ fusion protein, we PCR-amplified the 136 amino acid of mouse Hic1 POZ domain, including the NLS. For analysis of the SIRT1 promoter, a 2.1 kb promoter region was PCRamplified and subcloned into pGL2 (Promega). 
DNA-Damage Assays
Gene Knockdown in Untransformed, Normal Human Cells
We performed the knockdown with fresh-trypsinized cycling human fibroblast WI-38 cells without preseeding cells overnight. We prepared lipid-siRNA mixture using Lipofectamine-2000 (InVitrogen) as per specifications, then added 2.5 ml combined mixture to one million cells suspended in 10 ml Opti-MEM. Cells were cultured for 24 hr, and transfection medium was replaced with growth medium. Cells were allowed to grow for another 24 hr before analysis. For DNA-damage assays, we then treated cells with 20 M etoposide for 12 hr. Using this protocol, we can effectively knock down HIC1 or GAPDH with as little as 12.5 nM siRNA as final concentration in 12.5 ml medium.
Immunoprecipitation (IP), Immunohistochemistry (IHC), and Western Blot
For protein interaction analysis, we typically transfected one million COS-7 cells with CMV-Sirt1 expression vector (Upstate Biotech), using Lipofectamine 2000 (InVitrogen) for 4 hr, followed by infection with Ad/HIC1 overnight. We used 100-200 g cell lysate for IP with HIC1 antibody and pulled down the immune complex with protein A-agarose beads (Upstate Biotech). For IP of endogenous Hic1 in NIH 3T3 cells, we used about 1 mg of nuclear extract to pull down Hic1. For analysis of interaction with HA-POZ fusion protein, we cotransfected CMV-Sirt1 with an HA-POZ construct and used 500 g of cell lysate for IP with a mouse HA antibody (Santa Cruz). For analysis of p53 acetylation, we either performed Western blot directly on nuclear extracts or IP of total p53 with DO-1 antibody (NeoMarker) from 500 g cell lysate, then using elutes for Western. The following antibodies were used for Western blots: SIRT1 (Upstate Biotech), acetylated p53 (Cell Signaling), GAPDH (Travigen), lamin A/C (Santa Cruz), Noxa (Imgenex), Bax (Santa Cruz), and BCL-2 (Oncogene). Nuclear extracts for Western analysis were prepared using NE-PAR Nuclear and Cytoplasmic Extraction Reagents (Pierce). Western blots were quantitated with Scion Image. IHC was performed as previously described (Chen et al., 2003) .
Chromatin Immunoprecipitation and ChIP upon ChIP
We carried out ChIP using a procedure described previously (Chen and Townes, 2000) . For ChIP upon ChIP assay, we used five times more input chromatin than the single ChIP as starting material. After the first round of immunoprecipitation, the thoroughly washed immunocomplex bound was eluted twice with G buffer (0.1 M glycine, pH 2.50). The elutions were combined and neutralized with N buffer (2 M Tris, 0.4 M NaOH) and then diluted 1:10 with ChIP buffer for the second round of immunoprecipitaion, as in a single ChIP assay.
Reporter Assay
We performed luciferase analysis in COS-7 cells using the DualLuciferase Reporter Assay System (Promega). We cotransfected 1.5 × 10 4 cells with 1 g each of reporter constructs with 10 ng pRL-TK (Promega) for 4 hr using Lipofectamine Plus (InVitrogen), followed by infection with adenoviral vectors for 24 hr. We then harvested cells for luciferase assay as per the manufacturer's specifications. Relative luciferase activity was reported as a ratio of firefly over Renilla luciferase readouts.
Northern Blot
We isolated total RNA from MEF using Trizol (InVitrogen), used the Random Primed DNA Labeling Kit (Roche) to synthesize complementary DNA probe, and hybridized the membrane with UltraHyb buffer (Ambion). The blot was analyzed on a PhosphorImager.
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